Clinical trial · Observational
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors
NCT01201096CI-TRIAL-00003960NEO-LEBEunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to show the tumor free long term survival of patients with isolated non-resectable liver metastases of neuroendocrine tumors after neo-adjuvant radio receptor treatment and following liver transplantation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver | — | UNRESOLVED | — |
| Metastasis | — | UNRESOLVED | — |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 177Lutetium | Radiation | — | UNRESOLVED |
| Liver transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- peptide radioreceptor therapy and liver transplantation
- interventionNames
- Radiation: 177Lutetium
- Procedure: Liver transplantation
Primary outcomes (1)
- measure
- tumor free survival
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- quality of life
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 to 60 years * neuroendocrine Tumor with low or intermediate malignant histological appearance * primary tumor removed, no extrahepatic tumor * liver metastasis not resectable * positive evaluation for liver transplantation * primary tumor drained by vena porta * tumor load within the liver \< 50% * stable disease after receptor therapy with 177 Lutetium for 6 month Exclusion Criteria: * prognostic relevant second tumor disease * pregnancy * undifferentiated neuroendocrine carcinoma (WHO II, G3) * renal insufficiency \> second degree * progressive carcinoid conditioned heart disease (\>NYHA II) * Karnofsky-Index \< 60
References
Publications (0)
Data not yet available
No reference posted for this study.